4-[(1H-benzoimidazol-2-ylsulfanyl)-acetyl]-morpholine | 30065-31-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 4-[(1H-benzoimidazol-2-ylsulfanyl)-acetyl]-morpholine
• 英文别名: 2-(1H-benzoimidazol-2-ylsulfanyl)-1-(morpholin-4-yl)ethanone；2-(1H-benzimidazol-2-ylsulfanyl)-1-(morpholin-4-yl)ethanone；2-(1H-benzimidazol-2-ylsulfanyl)-1-morpholin-4-ylethanone
• CAS: 30065-31-7
• 化学式: C₁₃H₁₅N₃O₂S
• 分子量: 277.347
• InChiKey: KBIRGWLDHMLJDW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  83.5
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  吗啉 、 噻唑并[2,3-b]苯并咪唑-3(2H)-酮 生成 4-[(1H-benzoimidazol-2-ylsulfanyl)-acetyl]-morpholine
  参考文献：
  名称：

  Mustafa,A. et al., Justus Liebigs Annalen der Chemie, 1970, vol. 740, p. 132 - 141

  摘要：

  DOI：

文献信息

• [EN] SELECTIVE HDAC6 INHIBITOR<br/>[FR] INHIBITEUR SÉLECTIF DE HDAC6
  申请人：ROYAL COLLEGE SURGEONS IRELAND

  公开号：WO2022129256A1

  公开（公告）日：2022-06-23

  A compound, which is according to formula (I) or is a pharmaceutically acceptable salt, solvate, ester or pro-drug thereof, for use as a medicament, wherein either (i) NR1R2together forms a 5- or 6- membered heterocyclic ring or (ii) R1and R2are independently selected from H and C1 to C12 alkyl; A is a non-aromatic ring, an aromatic ring or a double bond; X is NR3, S or O, where R3is selected from H and C1 to C12 alkyl; Y is S, NR4, CR4R5, or O, where R4and R5are independently selected from H and C1 to C12 alkyl; and Z is (CR6R7)n where R6and R7are independently selected from H and C1 to C12 alkyl and n is an integer from 1 to 6. The compounds of formula I are particularly useful for the treatment of cancer, neurodegenerative diseases and/or inflammation.

  根据公式(I)或其药学上可接受的盐、溶剂化合物、酯或前药，用作药物的化合物，其中要么(i) NR1R2共同形成5或6元杂环环，要么(ii) R1和R2分别选择自H和C1到C12烷基；A是非芳香环、芳香环或双键；X是NR3、S或O，其中R3选择自H和C1到C12烷基；Y是S、NR4、CR4R5或O，其中R4和R5独立选择自H和C1到C12烷基；Z是（CR6R7）n，其中R6和R7独立选择自H和C1到C12烷基，n是1至6的整数。公式I的化合物特别适用于治疗癌症、神经退行性疾病和/或炎症。
• Design, synthesis, and biological activity studies on benzimidazole derivatives targeting myeloperoxidase
  作者：Merve Saylam、Fadime Aydın Köse、Aysun Pabuccuoglu、Duygu Barut Celepci、Muhittin Aygün、Varol Pabuccuoglu

  DOI：10.1016/j.ejmech.2022.115083

  日期：2023.2

  injury, multiple sclerosis, cardiovascular and neurodegenerative diseases. Therefore, the enzyme currently draws attention as a potential therapeutic target. In this study, isomeric 1,3-dihydro-2H-benzo[d]imidazole-2-thione derivatives having amide, hydrazide and hydroxamic acid groups either on nitrogen or on sulphur atom were designed and their inhibitory activity was determined on chlorination and peroxidation

  髓过氧化物酶 (MPO) 通过产生的次氯酸 (HOCl) 氧化吞噬溶酶体中微生物的重要分子，从而在人体抗菌系统中发挥关键作用。然而，MPO 可以释放到吞噬细胞外并产生反应性中间体，导致组织损伤。MPO 作为组织损伤的局部介质，与肾损伤、多发性硬化、心血管和神经退行性疾病等炎症性疾病有关。因此，该酶目前作为潜在的治疗靶点而备受关注。在这项研究中，同分异构的 1,3-dihydro-2 H -benzo[ d设计了在氮原子或硫原子上具有酰胺、酰肼和异羟肟酸基团的咪唑-2-硫酮衍生物，并测定了它们对 MPO 的氯化和过氧化循环的抑制活性。在这些化合物中，2-(2-thioxo-2,3-dihydro-1H-benzo[d]imidazole -1-yl )acetohydrazide (C19)被发现是两个循环中最活跃的抑制剂。
• SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION
  申请人：Siga Technologies, Inc.

  公开号：EP2293671A1

  公开（公告）日：2011-03-16
• SAMLL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION
  申请人：Byrd Chelsea M.

  公开号：US20110158940A1

  公开（公告）日：2011-06-30

  Methods and pharmaceutical compositions for treating viral infections, by administering certain compounds in therapeutically effective amounts are disclosed. Methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by flavivirus is disclosed, i.e., including but not limited to, Dengue virus, West Nile virus, yellow fever virus, Japanese encephalitis virus, and tick-borne encephalitis virus.
• US9029376B2
  申请人：——

  公开号：US9029376B2

  公开（公告）日：2015-05-12